AFCR will celebrate its 20 Year Anniversary in 2025. In those 20 years, AFCR has been focused on funding cancer research, especially those cancers prevalent in Asian populations. Here is a snapshot of the research fields we will fund during 2024-2025.
CHANGING THE ONCOLOGY TREATMENT PARADIGM FOR ORAL CANCERS:
Placed on tumors, a novel penny-sized uniquely engineered system ensures targeted and timely delivery of treatments, sparing patients the severe damage of surgery and the toxicities of anti-cancer agents throughout their body.
CONVERGENCE OF WESTERN SCIENCE AND TRADITIONAL CHINESE MEDICINE — BOTANICAL CANCER DRUG PLATFORM:
Provides a holistic or systems biology approach to cancer treatment, as with first drug, YIV-906 that potentiates other anti-tumor therapies and protects the body from the harsh effects of therapy.
REVOLUTIONARY CLINICAL RESEARCH MODEL TO DEFEAT DEADLIEST BRAIN CANCER:
Efficiently and simultaneously tests most promising treatments that lowers the cost, time and number of patients required to evaluate new potentially effective therapies, giving patients the greatest hope their lives can be saved.
ENGAGING THE IMMUNE SYSTEM TO TREAT GASTROINTESTINAL CANCERS:
A first-in-class bi-specific antibody links cancer cells with the fighter ‘T’ immune cells is in clinical trials treating patients with advanced gastrointestinal cancers who have limited treatment options to save their lives. Early trial results show the targeted therapy is safe and the trial monitoring board approves continuation.
PARTNERSHIP WITH CITY UNIVERSITY OF HONG KONG (CITYU):
AFCR and CityU established a closer collaboration and jointly created the Innovation Series in Biomedicine, that promotes academic innovations and entrepreneurship activities in Hong Kong, featuring genomic and precision medicine leaders from Asia and the U.S.
